Physician profile
Saryna Young
NPI 1407962764
$12,522.32
in general payments reported to CMS, 2019-2025
36 companies · $2,265 in 2025
The $2,265 reported for 2025 was more than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $471 · 2021: $1,292 · 2022: $2,979 · 2023: $2,869 · 2024: $1,628 · 2025: $2,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,467 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,467.22 |
| Education | $294.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,493.20 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $1,507.47 | 2019-2025 | Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $1,229.84 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $989.60 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $806.57 | 2019-2025 | Botox |
| Sun Pharmaceutical Industries INC. | $651.22 | 2020-2025 | Absorica Ld, Winlevi, Odomzo |
| Incyte Corporation | $617.36 | 2021-2025 | Opzelura |
| Genzyme Corporation | $571.00 | 2019-2025 | |
| Amgen INC. | $522.61 | 2021-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $333.74 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $328.41 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $294.44 | 2021-2025 | Cabtreo, Jublia |
| Almirall LLC | $288.93 | 2020-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $230.48 | 2020-2024 | Taltz, Olumiant |
| Biofrontera INC. | $220.70 | 2021-2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $179.66 | 2020-2022 | |
| Journey Medical Corporation | $175.19 | 2022-2025 | |
| Aclaris Therapeutics, INC. | $161.81 | 2019 | |
| Arcutis Biotherapeutics, INC. | $111.88 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $80.52 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.71 | 2022-2023 | Sotyktu |
| Musculoskeletal Transplant Foundation INC. | $70.26 | 2021-2024 | |
| Revance Therapeutics, INC. | $67.46 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.77 | 2022 | |
| Celgene Corporation | $60.75 | 2019 | |
| Dermavant Sciences, INC. | $59.92 | 2022-2024 | Vtama |
| Epi Health, LLC | $59.38 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $55.10 | 2020-2021 | |
| Botanix Sb INC | $52.86 | 2025 | Sofdra |
| Leo Pharma INC. | $48.38 | 2024 | Adbry |
| Ucb, INC. | $32.25 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.87 | 2024 | Clear+Brilliant |
| Acelrx Pharmaceuticals, INC. | $18.73 | 2022 | |
| Medline Industries Lp | $15.08 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $13.68 | 2019 | |
| Organon LLC | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saryna Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.